Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Vaccines, Blood & Biologics

Review Committee Meeting Summary, January 20, 2010 - Menveo

BLA 125300_0
Novartis ACYW-135 Mening Vaccine

January Review Committee Meeting Summary




Call in


International Call in - Toll


Wednesday, January 20, 2010


3:00 – 4:00  PM EST


WOC1 200S



Participant Passcode

Leader pass code --b(4)---



  1. Attendance –

Al-Humadi, Nabil,Tox
Bash, Margaret - Clin
Blake, Milan- hSBA Product
Burns, Drusilla -Assay Validation
Campbell, Karen- DPQ
Fiore,  Cara -  RPM
Freedberg, Daron- Product
George,  Joseph- Facilities
Gupta,  Rajesh- DPQ
Krasnicka, Barbara- Stat
Lee, Robert- Product
Miller, Catherine- APLB
Roecklein, Tina- Product Coord
Senthil, Geetha- OBE/DE Rep
Sun, Wellington- Director, DVRPA
Vann, Willie- CHAIR
White, Janet- BIMO
Valenti, Elizabeth- RPM

  1. Review of latest submission – if you have material in the latest submission that you are responsible for reviewing, please insure it is covered in your review.  All reviews to be finished (except label) by Wednesday January 26, 2010 so the action package can be routed Friday, January 29, 2010.
  2. Resolution of problems with clinical and statistical reviews
  3. Team Reports and Review Status
  1. Clinical and PI – The clinical reviewer points out that that the statistical reviewer expressed her concern about the neurologic events and suicide rates in the Menveo arm, however, there is not an imbalance in these events and it will be clarified in the clinical review.  Novartis will have to perform a large safety study as part of a post marketing commitment, which will monitor these events.  Regarding the immunologic data in the P18 study, the data suggests that concomitant administration with TdaP and one dose of Gardasil does not interfere with the Menveo response.  But, there may be interference with acellular pertussis antigens filamentous hemagglutinin and pertactin when TdaP is administered concomitantly with Menveo and Gardasil.  CBER has asked Novartis to add another post marketing study to evaluate this.  The data is inadequate to determine the responses of the other vaccines. 
    We have had one cycle with the package insert with the sponsor and will continue to work on it.
  2. Statistical - done
  3. BIMO - done
  4. DPQ – The DPQ director is reviewing this review.  The Lot Release Protocol has been reorganized and was sent to Joe Quander for final review.  There are problems with in-support testing, but these can/will be worked out with Novartis post-license.
  5. CMC– Robert Lee.  Review completed
  6. CMC – Daron Freedberg. Review not completed/
  7. DMPQ – Joe George.  Will upload and provide the inspection tab by Wednesday the 28th.
  8. Labeling – APLB review done
  9. Toxicology  - done
  10. Reproductive Toxicology - done
  11. Assay Validation – done (except hSBA). hSBA assay – Dr. Baylor will have to review Dr. Blake’s review.  Dr. Blake should send it to him immediately.
  12. OBE/PMC – PBE/DE has information in the newest amendment that will have to be reviewed. 


Contact FDA

(800) 835-4709
(240) 402-8010
Consumer Affairs Branch (CBER)

Division of Communication and Consumer Affairs

Office of Communication, Outreach and Development

Food and Drug Administration

10903 New Hampshire Avenue

Building 71 Room 3103

Silver Spring, MD 20993-0002

Page Last Updated: 09/25/2013
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English